Woodcock's Prophesy Comes True: US FDA ANDA Approvals Decline From Record Levels
Executive Summary
Janet Woodcock’s 2019 prediction that record ANDA approval volumes would not continue is confirmed with the FY 2020 approval total down 21% from the previous year.
You may also be interested in...
User Fee Renewal Negotiations Beginning This Week
Talks between US FDA and industry to extend the generic drug and prescription drug user fee programs may last into 2021.
Generic Drug Approvals Still Winning The Pandemic At US FDA
Productivity remains high as full ANDA approvals reached a FY 2020 peak and complete responses dropped to another low in June.
Teva’s Rx For GDUFA III: Treat Complex Generics More Like NDAs
New drug review elements that could benefit complex generics include a two-month filing review period before the user fee clock is triggered, more interaction between the agency and a sponsor during the review, and an opportunity for a company to have in-depth discussions with the FDA after receipt of a complete response letter, Teva’s Scott Tomsky says at kick-off meeting for next iteration of the generic drug user fee agreement.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: